Hanmi Science Proposes Dismissal of Hanmi Pharm CEO Park Jae-hyun and Chairman Shin Dong-guk Amidst Internal Power Struggle

Reporter Kim Jisun / approved : 2024-10-02 03:12:46
  • -
  • +
  • 인쇄

(Photo= Yonhap news)

 

[Alpha Biz= Reporter Kim Jisun] Hanmi Science, led by Vice President Im Jong-hoon, is pushing to remove Hanmi Pharm CEO Park Jae-hyun and Chairman Shin Dong-guk from the board amidst a conflict with a "three-party alliance" consisting of Shin Dong-guk, along with his daughters Song Young-sook and Lim Joo-hyun.

On the 30th, Hanmi Science sent a formal request to Hanmi Pharm, demanding the convening of an extraordinary general meeting to discuss the dismissal of Park and Shin. The company criticized Shin, stating he is a "major shareholder lacking expertise and experience in R&D," highlighting concerns that he criticized Park for spending "too much" on Hanmi Pharm’s core competency—R&D. This criticism points to discussions that undermine both the interests of the company’s members and shareholders regarding major management decisions that secure the company's future value.

Hanmi Science has proposed current Hanmi Science Vice President Park Jun-seok and Hanmi Precision Chemical CEO Jang Young-gil as new board candidates, as they have previously collaborated closely with Im Jong-hoon during his tenure as CEO of Hanmi Healthcare and Hanmi Precision Chemical.

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

SK hynix and Naver Cloud Join Forces to Accelerate Next-Generation AI Memory Solutions2025.09.11
HD Hyundai Heavy Industries Strike Clash Leaves Union Member Injured2025.09.11
Chartered Korean Air Flight to Repatriate Over 300 Koreans Detained at Georgia Battery Plant; Industry Fears Multi-Billion Losses Amid Construction Halt2025.09.11
Chong Kun Dang Chairman Transfers Entire Stake in Kyungbo Pharmaceutical to Children, Expands IT Subsidiary Portfolio2025.09.11
Harim Holdings to Acquire Entire Harim USA Stake from Subsidiary Farmsco2025.09.11
뉴스댓글 >